[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Federal University of São Paulo\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":429},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,50,81,105,135,158,188,217,245,271,299,323,354,383,403],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100054302",false,"NCT07699679","Photobiomodulation in Coronary Artery Bypass Grafting With No-Touch vs Conventional Saphenous Vein Harvesting.","Impact of Photobiomodulation in Coronary Artery Bypass Surgery: Comparison Between No-Touch and Conventional Saphenous Vein Harvesting Techniques on Clinical Outcomes, Functional Capacity, and Wound Healing: A Randomized Clinical Trial","PHOTON","Inclusion Criteria:\n\n* Patients diagnosed with coronary artery disease scheduled to undergo elective coronary artery bypass grafting (CABG)\n* Use of the saphenous vein as a graft for myocardial revascularization\n* Ability to understand the study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Emergency coronary artery bypass surgery\n* Previous surgery in the lower limb that prevents saphenous vein harvesting\n* Active infection at the surgical site or lower limb\n* Severe peripheral arterial disease in the lower limbs\n* Hemodynamic instability preventing study protocol procedures\n* Participation in another interventional clinical trial that may interfere with the outcomes of this study\n* Patients unable to perform postoperative functional capacity assessments\n* Individuals with highly pigmented skin or sensibility that may alter light absorption and penetration of the photobiomodulation therapy.","ALL","18 Years","75 Years",{"count":20,"type":21},292,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized, double-blind clinical trial aims to evaluate the impact of photobiomodulation therapy on postoperative outcomes in patients undergoing coronary artery bypass grafting (CABG). The study will compare two techniques for saphenous vein graft harvesting: the conventional technique and the no-touch technique. Participants will be randomly allocated into four groups: conventional harvesting with placebo, conventional harvesting with photobiomodulation, no-touch harvesting with placebo, and no-touch harvesting with photobiomodulation. The primary objective is to evaluate the effects of photobiomodulation on wound healing and postoperative complications related to the saphenous vein harvesting site. Secondary outcomes include clinical outcomes and functional capacity after surgery. The results may contribute to improving postoperative recovery and optimizing surgical strategies in patients undergoing myocardial revascularization.",[27,28,29],"Coronary Artery Disease","Coronary Artery Bypass Graft (CABG)","Surgical Wound Healing",[31,32,33,34,35,36],"Photobiomodulation","Low-Level Laser Therapy","Coronary Artery Bypass Grafting","Saphenous Vein Harvesting","No-Touch Technique","Wound Healing","NOT_YET_RECRUITING","2026-07-08",{"date":40,"type":41},"2026-07-13","ACTUAL",{"date":43,"type":21},"2026-08",{"date":45,"type":21},"2028-03",{"name":47,"class":48},"Federal University of São Paulo","OTHER",1,{"id":51,"slug":4,"hasResults":10,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":49},"100578004","NCT06805656","Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Antiretrovirals","Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Use of Antiretrovirals","Inclusion Criteria:\n\n\\- \\> 18 years old \\\u003C 65 years old Documented HIV-1 infection. Has voluntarily signed ICF. On HAART ≥ 2 years, without changes in the 24 weeks immediately prior to screening.\n\nHIV viral load \\\u003C50 copies\u002FmL, and never \\> 50 copies\u002FmL on 2 consecutive occasions in the last 2 years. CD4 count nadir.\n\n\\> 350 cells\u002F mm3 Current CD4 count \\> 500 cells\u002F mm3. R5 HIV-1 at Screening as defined by proviral DNA genotropism.\n\nExclusion Criteria:\n\n\\- Any evidence of an active AIDS-defining condition. Any significant acute medical illness in the past 8 weeks. Women who are pregnant or breastfeeding. Use of any of the following within 90 days prior to entry: systemic cytotoxic chemotherapy; investigational agents; immunomodulators (colonystimulating factors, growth factors, systemic corticosteroids, HIV vaccines, immune globulin, interleukins, interferons); coumadin, warfarin, or other coumadin derivative anticoagulants. Use of an agent definitely or possibly associated with effects on QT intervals: amiodarone, arsenic trioxide, astemizole, bepridil, chloroquine, chlorpromazine, cisapride, clarithromycin, disopyramide, dofetilide, domperidone, droperidol, erythromycin, halofantrine, haloperidol, ibutilide, levomethadyl, mesoridazine, methadone, pentamidine, pimozide, probucol, procainamide, quinidine, sotalol, sparfloxacin, terfenadine, thioridazine.\n\nReceipt of compounds with HDAC inhibitor-like activity, such as valproic acid or nicotinamide within the last 30 days. Potential participants may enroll after a 30-day washout period.\n\nKnown hypersensitivity to the components of gold salt, nicotinamide or its analogs.\n\nHepatitis B (HBsAg +) or Hepatitis C (HCV RNA +) infection. Known renal insufficiency defined as calculated creatinine clearance (Cockcroft Gault formula) \\\u003C60 mL\u002Fmin.\n\nSubjects with a laboratory abnormality grade 3 or 4 with the following exceptions: pancreatic amylase, cholesterol, triglyceride, gamma glutamyl transpeptidase, bilirubin.\n\nAny condition which, in the investigators opinion, could compromise the subject's safety or adherence to the trial protocol.","65 Years",{"count":58,"type":21},70,[60],"PHASE2","A modern and urgent challenge in fighting HIV infection is to achieve sustained HIV remission without the use of antiretrovirals. The investigators' preliminary data indicate that the use of combined strategies to mitigate the HIV proviral reservoir size among individuals with suppressive antiretroviral treatment achieved unprecedented results in the reduction of HIV DNA present in these cells and in the reduction of CD4 + and CD8 + T cell activation. Combined interventions include intensified antiretroviral treatment to mitigate residual HIV replication, use of a histone deacetylase inhibitor to interrupt viral latency, use of an anti-proliferative medication to reduce long-lived T cells that harbor HIV and a personalized dendritic cell therapy vaccine to eliminate cells with latent HIV infection or cells present in viral sanctuaries. Due to the good results obtained in the exploratory stage of the project, the investigators propose to expand it by recruiting a larger number of patient to confirm the previously obtained results and to generate new insights related to the mechanisms involved in viral latency, latency disruption and the effects of analytical treatment interruption of antiretrovirals among patients undergoing all above mentioned interventions.",[63,64],"Hiv","HIV I Infection",[66,67,68,69,70,71,72],"Dendritic Cell vaccination","antiretroviral intensification","Auranofin","Histone Deacetylase Inhibitor","residual viral replication","HIV sanctuaries","HIV latency","2026-05-28",{"date":75,"type":41},"2026-06-01",{"date":77,"type":21},"2026-07-01",{"date":79,"type":21},"2027-12-31",{"name":47,"class":48},{"id":82,"slug":4,"hasResults":10,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":49},"100628639","NCT07464262","Telemonitoring With CPAP in Severe Obstructive Sleep Apnea in Primary Health Care","Efficacy of Telemonitoring With CPAP in Severe Obstructive Sleep Apnea: A Randomized Controlled Trial in Primary Health Care","CPAP-APS","Inclusion Criteria:\n\n* Age between 18 and 75 years.\n* Diagnosis of severe obstructive sleep apnea (OSA) confirmed by polysomnography with apnea-hypopnea index (AHI) ≥30 events\u002Fhour.\n* New CPAP users (≤30 days since initiation of CPAP therapy).\n* Resident within the coverage area of the Southeast Regional Health Coordination (CRS Sudeste), São Paulo, Brazil.\n* Ability to understand and sign the informed consent form.\n\nExclusion Criteria:\n\n* Previous CPAP use for more than 30 days prior to enrollment.\n* Indication for bilevel ventilation (BiPAP) or non-invasive ventilation due to conditions such as hypoventilation syndromes, chronic hypercapnic COPD, or neuromuscular diseases.\n* Predominant central sleep apnea (≥50% central events) or Cheyne-Stokes respiration.\n* Recent unstable or severe comorbidity (e.g., decompensated heart failure, acute coronary syndrome within 30 days, stroke within 3 months).\n* Severe cognitive impairment or psychiatric disorder that prevents understanding of study procedures or adherence.\n* Conditions preventing safe use of CPAP mask (e.g., major craniofacial deformities, facial trauma, extensive facial skin lesions).\n* Inability to maintain follow-up in primary care services of CRS Sudeste.\n* Participation in another interventional clinical trial that may interfere with study outcomes.",{"count":89,"type":21},200,[24],"Obstructive sleep apnea (OSA) is a prevalent sleep disorder associated with cardiovascular, metabolic, cognitive, and psychological complications. Continuous Positive Airway Pressure (CPAP) therapy is the gold standard treatment for moderate to severe OSA; however, long-term adherence remains a major challenge, particularly in real-world primary care settings.\n\nThis study aims to evaluate the effectiveness of telemonitoring using CPAP devices in improving treatment adherence and clinical outcomes among patients with severe OSA receiving care within the Brazilian Primary Health Care system.\n\nThis randomized controlled trial will include 200 adult participants with severe OSA who are new users of CPAP therapy and are followed by primary health care units in the Southeast Regional Health Coordination of São Paulo, Brazil. Participants will be randomly allocated into two groups: a telemonitoring intervention group, monitored remotely through the AirView® platform and the myAir® application, and a control group receiving standard care without telemonitoring.\n\nPrimary outcomes include CPAP adherence and residual apnea-hypopnea index (AHI). Secondary outcomes include daytime sleepiness, sleep quality, mood, cognitive complaints, and patient perceptions of care. Quantitative clinical data will be collected through CPAP telemonitoring systems and standardized questionnaires, while qualitative data will be obtained through semi-structured interviews with patients and health professionals.\n\nThe results of this study may provide evidence supporting the integration of digital health technologies into primary health care services to improve adherence to CPAP therapy and optimize the management of obstructive sleep apnea in public health systems.",[93],"Obstructive Sleep Apnea (OSA)",[95],"CPAP Obstructive Sleep Apnea Telemonitoring Digital Health Sleep Apnea Primary Health Care Adherence Remote Monitoring","RECRUITING","2026-03-06",{"date":99,"type":41},"2026-03-11",{"date":101,"type":41},"2025-10-06",{"date":103,"type":21},"2027-07",{"name":47,"class":48},{"id":106,"slug":4,"hasResults":10,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":114,"conditions":115,"keywords":119,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":49},"100621914","NCT07376811","Effect Of Sleeping Posture Guidance On Sleep Quality In Patients With Rotator Cuff Syndrome","Effect Of Sleeping Posture Guidance On Sleep Quality In Patients With Rotator Cuff Syndrome Undergoing Physical Therapy: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Clinical and\u002For radiological diagnosis of Rotator Cuff Syndrome (RCS).\n* Presence of shoulder pain for at least 3 months (chronic pain).\n* Patients aged between 18 and 65 years.\n* Patients referred for conservative physical therapy treatment.\n* Ability to understand and answer the assessment questionnaires (PSQI, MSQ, ASES, and VAS).\n* Voluntarily signing the Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n* History of surgical procedures on the affected shoulder.\n* Presence of fractures or recent acute trauma in the shoulder or upper limb.\n* Associated neurological disorders, inflammatory systemic diseases (e.g., Rheumatoid Arthritis), or adhesive capsulitis (frozen shoulder).\n* Previous diagnosis of primary sleep disorders unrelated to pain (e.g., severe obstructive sleep apnea) already under clinical treatment.\n* Recent history of corticosteroid injections in the shoulder (within the last 3 months).",{"count":112,"type":21},64,[24],"This study investigates sleep quality in patients with Rotator Cuff Syndrome (RCS) undergoing physical therapy treatment. Existing literature presents a gap regarding longitudinal studies evaluating the impact of physical therapy and different sleeping positions on sleep quality within this specific population. The central hypothesis is that physical therapy, combined with guidance on the best sleeping positions, reduces pain, improves shoulder function, and consequently promotes an improvement in sleep quality for RCS patients over time. The justification for this research lies in the need to better understand the relationship between physical therapy and sleep quality in RCS patients, aiming for the development of more effective and less invasive interventions. Previous studies have demonstrated that chronic pain, a common symptom of RCS, is intrinsically linked to sleep disturbances, which can lead to deleterious effects such as dopamine reduction, alterations in the descending pain modulation system, and central sensitization. Improvements in sleep quality have been observed after surgical procedures such as shoulder arthroscopy and arthroplasty, often associated with improved function and pain reduction. Thus, this study seeks to longitudinally evaluate whether physical therapy is capable of promoting a sustained improvement in sleep quality for patients with RCS",[116,117,118],"Rotator Cuff Syndrome","Rotator Cuff Injury","Sleep Disorder (Disorder)",[120,121,122,123,124,125,126],"rotator cuff syndrome","sleep quality","sleeping position","physical therapy","randomized controlled trial","shoulder pain","rehabilitation","2026-01-25",{"date":129,"type":41},"2026-01-29",{"date":131,"type":21},"2026-03-01",{"date":133,"type":21},"2029-11-01",{"name":47,"class":48},{"id":136,"slug":4,"hasResults":10,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":144,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":49},"100611603","NCT07242729","Bone Marrow Aspirate Versus Platelet-Rich Fibrin for the Treatment of Chronic Plantar Fasciitis","Bone Marrow Aspirate Versus Platelet-Rich Fibrin for the Treatment of Plantar Fasciitis - A Double-Blind Randomized Clinical Trial","fasciitis","Inclusion Criteria:\n\n* Adults aged 18 to 75 years.\n* Clinical diagnosis of chronic plantar fasciitis for more than 6 months, confirmed by ultrasonography (increased plantar fascia thickness and hypoechogenicity).\n* Persistent heel pain refractory to conventional conservative treatment (stretching, orthotics, physical therapy, or corticosteroid injections).\n* Visual Analog Scale (VAS) pain score ≥ 4 at baseline.\n* Ability and willingness to comply with study procedures and follow-up assessments.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Previous foot or ankle surgery on the affected limb.\n* Acute trauma, infection, or ulceration in the region of the plantar fascia.\n* Systemic inflammatory diseases (e.g., rheumatoid arthritis, lupus, psoriatic arthritis).\n* Metabolic or endocrine disorders interfering with healing (e.g., diabetes mellitus with poor glycemic control, thyroid disorders).\n* Current use of systemic corticosteroids, immunosuppressants, or anticoagulants.\n* Active neoplasia or hematologic disorders.\n* Pregnancy or breastfeeding.\n* Peripheral vascular disease or neuropathy affecting the lower limbs.\n* Contraindications to local anesthesia or venipuncture.",{"count":143,"type":21},72,[24],"This randomized, double-blind clinical trial aims to compare the clinical and imaging effects of autologous bone marrow aspirate versus platelet-rich fibrin injections in patients with chronic plantar fasciitis. The procedures are performed under ultrasound guidance to ensure precision and safety. The study evaluates pain reduction, foot function, and ultrasonographic changes in the plantar fascia at follow-up intervals.",[147],"Plantar Fasciitis",[149],"Plantar Fasciitis; Bone Marrow Aspirate; Platelet-Rich Fibrin; Ultrasound-Guided Injection; Regenerative Medicine","2025-11-17",{"date":152,"type":41},"2025-11-21",{"date":154,"type":41},"2025-02-01",{"date":156,"type":21},"2028-02-01",{"name":47,"class":48},{"id":159,"slug":4,"hasResults":10,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":164,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":22,"phases":167,"briefSummary":169,"conditions":170,"keywords":173,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":49},"100592284","NCT06991426","Effects of CreaSafe® on Kidney, Muscle, and Cardiopulmonary Function in Athletes and COPD Patients","Effects of a New Creatine Formulation (CreaSafe®) on Kidney Function, Skeletal Muscles, and Cardiopulmonary Function in Athletes and Patients With COPD","Inclusion Criteria:\n\n* resistance-trained athletes middle- and long-distance runners severe and\u002For very severe COPD\n\nExclusion Criteria:\n\n* Non-athletes and individuals without a diagnosis of COPD",true,{"count":166,"type":21},140,[168],"PHASE4","Creatine supplementation (CS) offers numerous health benefits, with no proven side effects reported to date. CS positively impacts all organs and systems of the body. However, there is an ongoing effort among several creatine-producing companies to develop increasingly pure creatine formulations that generate fewer renal metabolites. Therefore, this study aims to evaluate the effects of a new creatine formulation, CreaSafe®, synthesized by the Chinese company Wenda®, on kidney function in athletes and patients with chronic obstructive pulmonary disease (COPD), as well as its effects on skeletal muscles and cardiopulmonary function. Regarding the athletes (Study 1), the sample will consist of 80 healthy athletes (40 strength-training athletes and 40 middle- and long-distance runners). Among each group of 40 athletes, 20 will receive CreaSafe® creatine (0.03 g\u002Fkg\u002Fday), while the other 20 will receive a placebo (microcrystalline cellulose; 0.03 g\u002Fkg\u002Fday), for 90 days, orally administered in water in the morning (between 7:00 a.m. and 9:00 a.m.). For the COPD patients (Study 2), 60 patients with severe and\u002For very severe COPD will be recruited. Of these, 30 will receive CreaSafe® creatine (0.03 g\u002Fkg\u002Fday), while the other 30 will receive placebo (microcrystalline cellulose; 0.03 g\u002Fkg\u002Fday), also administered orally in water for 90 days in the morning (between 7:00 a.m. and 9:00 a.m.). The supplementation period for both studies will last 90 days, with assessments performed at baseline and after 90 days. Kidney function will be evaluated through urinalysis (Urine Type I), the balance of pro- vs. anti-inflammatory cytokines, and levels of urea, creatine kinase (CK), and creatinine. Body composition will be assessed using octopolar and multifrequency bioimpedance, along with circumference measurements of body segments. Muscle strength of different muscle groups will be assessed using the E-lastic dynamometer. Biomarkers of skeletal muscle degradation and recovery will also be measured in plasma, including CK, lactate dehydrogenase (LDH), urea, myoglobin, and the levels of IL-1beta, IL-4, IL-6, IL-10, TNF-alpha, Atrogin-1, MuRF-1, and GDF-8 (myostatin). Whole blood analysis (erythrocytes, leukocytes, and platelets) will be performed using a fully automated blood analyzer (Sysmex XS 800i). Pulmonary function will be assessed through pre- and post-bronchodilator spirometry, as well as maximal inspiratory (PIMax) and expiratory (PEMax) pressures using a manovacuometer. Cardiovascular function will be evaluated using electrocardiography (ECG) and cardiovascular hemodynamics assessed by impedance cardiography (PhysioFlow). GraphPad Prism 5.0 software will be used for statistical analyses and graph generation. Paired Student's t-tests will be used to compare pre- and post-intervention values within each group, and unpaired Student's t-tests will be used to compare deltas between the CreaSafe® and placebo groups. Statistical significance will be considered at p ≤ 0.05.",[171,172],"Copd","Athletes",[174,175,176,177,178,179],"creatine","supplementation","kidneys","heart","lungs","hematology","2025-05-23",{"date":182,"type":41},"2025-05-28",{"date":184,"type":21},"2025-07",{"date":186,"type":21},"2025-10",{"name":47,"class":48},{"id":189,"slug":4,"hasResults":10,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":164,"sex":194,"minAge":195,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":22,"phases":199,"briefSummary":200,"conditions":201,"keywords":205,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":4},"100590715","NCT06971029","IMPACT OF SUPPLEMENTATION WITH LOW MOLECULAR WEIGHT HYDROLYZED COLLAGEN AND VERISOL ON THE EXPRESSION OF LINES, SKIN QUALITY, AND LEVELS OF KLOTHO, VEGF, AND TGF-BETA IN THE EYE REGION","Effects Of Supplementation With New Technology for Obtaining Low Molecular Weight Hydrolyzed Collagen Vs. Verisol Collagen on Expression Lines, Skin Quality in the Orbicularis Oculi Region, And Serum Levels of Klotho, VEGF, and TGF-Beta","Inclusion Criteria:\n\n* \"Inclusion criteria require that volunteers be between 35 and 58 years old, have been sedentary for at least one year, and, after reading and understanding all stages of the study, agree to and sign the informed consent form (ICF).\n\nExclusion Criteria:\n\n* \"Exclusion criteria include undergoing facial aesthetic procedures involving hyaluronic acid or botulinum toxin, being an active or passive smoker within the past 3 years, using protein- or amino acid-based supplements within the past 6 months, or using cosmetics with skin-repairing properties in the orbicularis oculi region.","FEMALE","35 Years","58 Years",{"count":198,"type":21},150,[168],"Skin is the largest organ of the human body and performs various vital functions, including protection against external agents, regulation of body temperature, and sensory perception. As we age, our skin undergoes a series of changes that can be noticeable both visually and physically. One of the most evident changes is the appearance of wrinkles and fine lines, resulting from decreased skin elasticity and reduced production of collagen and elastin. Nutrition plays a key role in skin health, influencing its structure, function, and ability to defend against damage and diseases. However, it is unknown to what extent supplementation with different types of collagens can attenuate these effects in middle-aged women. Therefore, the present study aims to recruit 150 middle-aged women (35-58 years old) who will be randomized into three groups, Verisol Collagen 2.5 g\u002Fday, Peptech Collagen 2.5 g\u002Fday, and Peptech Collagen 10 g\u002Fday, 7 days a week, for 3 months. Skin hydration, oiliness, and flexibility, as well as the number and depth of expression lines, will be evaluated, along with plasma levels of Klotho, VEGF, and TGF-beta. Data will be analyzed, and graphs constructed using GraphPad Prism 5.0 software (California, USA). The normality distribution of the data will be assessed by the Kolmogorov-Smirnov test. Data with parametric distribution will be subjected to paired Student's t-test for intragroup comparison, and unpaired t-test will be used for comparison between groups. Significance levels will be considered statistically different for p\\\u003C0.05.",[202,203,204],"Skin Health","Collagen Supplementation","Growth Factors",[206,207,208],"Skin health","collagen supplementation","growth factors","2025-05-13",{"date":211,"type":41},"2025-05-14",{"date":213,"type":21},"2025-06-09",{"date":215,"type":21},"2025-12",{"name":47,"class":48},{"id":218,"slug":4,"hasResults":10,"nctId":219,"briefTitle":220,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":10,"sex":16,"minAge":222,"maxAge":223,"enrollmentInfo":224,"targetDuration":4,"studyType":22,"phases":226,"briefSummary":228,"conditions":229,"keywords":232,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":4},"100589691","NCT06957704","Evaluation of the Efficacy and Safety of Subcutaneous Ketamine in the Treatment of Depressive Episode With Suicidal Ideation and\u002For Behavior in Adolescents","Inclusion Criteria:\n\n* Age between 12 and 19 years.\n* Diagnosis of Major Depressive Episode, unipolar, made through the Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS-PL) administered by experienced evaluators, using DSM-5 criteria.\n* Under usual treatment for Major Depressive Episode, including clinically indicated psychopharmacological treatment and\u002For psychosocial treatment at one of the two collaborating clinics (DICA and Conversas de Vida \u002F Unifesp).\n* Score ≥ 25 on the MADRS (Montgomery-Åsberg Depression Rating Scale).\n* Score ≥ 28 on the CDRS (Children Depression Rating Scale).\n* Score ≥ 2 on the Columbia Suicide Severity Rating Scale (C-SSRS).\n* History of suicide attempt or significant suicidal ideation or planning with a plan or intention requiring emergency evaluation in the last 30 days.\n\nExclusion Criteria:\n\n* Presence of the following psychiatric comorbidities: Autism Spectrum Disorder, Bipolar Disorder, Schizophrenia, Schizoaffective Disorder, or psychiatric disorder secondary to physical illness, and history of ketamine or other substance abuse or dependence in the last 6 months.\n* Presence of Intellectual Disability (assessed by IQ testing).\n* Presence of the following clinical comorbidities: history of myocardial infarction, congenital heart disease, decompensated cardiac arrhythmia, decompensated hypertension, porphyria, stroke, brain trauma with loss of consciousness, intracranial hypertension, hydrocephalus, central nervous system tumors, or central nervous system abnormalities.\n* Previous treatment for depression with esketamine.\n* Allergy to esketamine.\n* If female: pregnancy or breastfeeding.","12 Years","19 Years",{"count":225,"type":21},60,[227],"PHASE3","Evaluate the efficacy and safety of subcutaneous ketamine added to usual treatment in the management of depressive episodes with suicidal ideation or behavior in adolescent patients, compared to usual treatment added to placebo (midazolam).",[230,231],"Depressive Disorder","Suicidal Ideas",[233,234,235,236],"Adolescent","Ketamine","Major Depressive Disorder","Midazolam","2025-05-02",{"date":239,"type":41},"2025-05-04",{"date":241,"type":21},"2025-05",{"date":243,"type":21},"2028-04",{"name":47,"class":48},{"id":246,"slug":4,"hasResults":10,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":22,"phases":254,"briefSummary":255,"conditions":256,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":49},"100563081","NCT06611527","Positive Pressure Therapy to Optimize LUNG Function After Heart Surgery","Comparison Between Two Methods of Positive Pressure Therapy in the Prevention of Pulmonary Complications in the Immediate Postoperative Period of Cardiac Surgery: a Prospective, Randomized Clinical Trial","PRO-LUNGHS","Inclusion Criteria:\n\n* Immediate postoperative period of myocardial revascularization and\u002For valve replacement or plastic surgery;\n* Patients in the preoperative period at risk of developing pulmonary complications, characterized by the presence of at least 2 of the following risk factors: age ≥ 70 years, productive cough, diabetes, history of smoking, chronic obstructive pulmonary disease (COPD) defined by forced expiratory volume in 1 second (FEV1) lower than 75% of predicted, body mass index (BMI) ≥ 27 kg\u002Fm2, or only FEV1 lower than 80% and FEV1\u002Fforced vital capacity (FVC) ratio lower than 70% of predicted; OR patients in the postoperative period (up to 12 hours after extubation) with mild to moderate complications characterized by a pulmonary complication score lower than 3.\n\nExclusion Criteria:\n\n* Hemodynamic instability characterized by mean arterial pressure (MAP) lower than 60mmHg and\u002For acute arrhythmia of any etiology;\n* Need for intra-aortic balloon;\n* Duration of invasive mechanical ventilation exceeding 24 hours after surgery;\n* Pulmonary complication score ≥ grade 3;\n* Presence of signs of acute respiratory failure, such as respiratory rate (f) ≥ 25 breaths\u002Fmin and use of accessory muscles;\n* Chest tube with air leak;\n* Use of a pacemaker or implantable or external cardioverter-defibrillator.",{"count":253,"type":21},156,[24],"The most common cardiac surgeries are myocardial revascularization and valve replacement or plastic surgery. In the postoperative period of cardiac surgeries, the incidence of pulmonary complications ranges from 30% to 50% and is associated with increased length of hospital stay and morbidity and mortality. To reduce or minimize the occurrence of these complications, respiratory physiotherapy employs positive pressure reexpansion therapies, such as continuous positive airway pressure (CPAP) and positive pressure support with positive end-expiratory pressure (PS+PEEP).\n\nThe goal of this clinical trial is to compare the effects of two positive pressure therapies, CPAP versus PS+PEEP, on the incidence of pulmonary complications in patients in the postoperative period of myocardial revascularization and valve replacement or plastic surgery, with mild to moderate pulmonary dysfunction.\n\nThe main question it aims to answer is: Do patients in the immediate postoperative period of myocardial revascularization or valve replacement\u002Fplastic surgery, exhibiting mild to moderate pulmonary dysfunction, experience a comparable reversal of pulmonary conditions when treated with PS+PEEP versus CPAP?\n\nParticipants will undergo the following assessments: spirometry, respiratory muscle strength testing, handgrip strength testing, and electrical impedance tomography.\n\nIn the immediate postoperative period, participants will be randomized into two treatment groups: • Control Group PS+PEEP - application of 4 sets of 20 repetitions with PS to provide a tidal volume equal to 10ml\u002Fkg of predicted body weight, PEEP equal to 10 cmH2O, and inspired oxygen fraction (FiO2) to achieve peripheral oxygen saturation (SpO2) between 92-94%; • Experimental Group CPAP - application of CPAP at 10 cmH2O with FiO2 to achieve SpO2 between 92-94% for 30 minutes.",[257,258,259,260,261,262],"Postoperative Period","Physical Therapy Modalities","Continuous Positive Airway Pressure","Respiratory Function Tests","Pulmonary Atelectasis","Heart Surgery","2025-04-08",{"date":265,"type":41},"2025-04-10",{"date":267,"type":41},"2025-01-08",{"date":269,"type":21},"2027-12",{"name":47,"class":48},{"id":272,"slug":4,"hasResults":10,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":10,"sex":16,"minAge":277,"maxAge":278,"enrollmentInfo":279,"targetDuration":4,"studyType":22,"phases":281,"briefSummary":282,"conditions":283,"keywords":286,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":298},"100554933","NCT06505525","Combined Intra- and Extra-articular ACL Reconstruction Versus Isolated Intra-articular ACL Reconstruction","Combined Intra- and Extra-articular ACL Reconstruction Versus Isolated Intra-articular ACL Reconstruction: Prospective Multicenter Randomized Clinical Trial With Hamstring Autograft","Inclusion Criteria\n\nPatients from the hospital's demand (emergency care and outpatient care) and from CROSS (Center for Regulation of Health Service Offers) who present one or more risk factors will be included:\n\n* Age (Female 14 years - 25 years and Male 16 years - 25 years);\n* Pivot-shift test \\> 2;\n* Chronic ACL injury (\\>12 months);\n* Athlete (Tegner Scale ≥ 7);\n* Tibial slope \\> 12 degrees;\n* Recurvatum \\> 5 degrees and \\\u003C 15 degrees (asymmetric);\n* Ligamentous Hypermobility (Beighton Scale \\> 5).\n\nNon-Inclusion Criteria\n\n* Individuals over 40 years of age will not be included;\n* ACL revision;\n* PCL injury (grade 2 and 3);\n* MCL injury (grade 2 and 3) or (grade 1 with valgus aligned axis);\n* CPL injury (grade 2 and 3 according to Fanelli classification);\n* Recurrent patellar dislocation;\n* Severe chondral lesion (ICRS grade 3 and 4) larger than 1cm2;\n* Previous ipsilateral knee surgery;\n* Kellgren Lawrence grade 3 or more;\n* Autoimmune\u002Frheumatologic inflammatory disease;\n* Contralateral knee ligament injury;\n* Malalignment \\> 5 degrees clinical asymmetry between limbs or symmetric \\> 10 degrees axis deviation to varus (corresponding to \\> 4 degrees varus between the anatomical axis of the femur and the anatomical axis of the tibia in the clinical examination) or \\> 10 degrees axis deviation to valgus (corresponding to \\> 16 degrees valgus between the anatomical axis of the femur and the anatomical axis of the tibia in the clinical examination);\n* Graft diameter \\\u003C 7 mm;\n* BMI \\> 35 or \\\u003C 18;\n* Active or undergoing treatment for malignant neoplasia;\n* Pregnancy or suspected pregnancy;\n* Psychiatric disorders.\n\nExclusion Criteria\n\nLeave of absence from work due to disability or reduced income assistance (worker's compensation) whenever one of the investigators considers that the participant may be simulating a worse health condition than reality in order to receive financial assistance with work leave.","14 Years","40 Years",{"count":280,"type":21},146,[24],"Abstract\n\nIntroduction: Autologous hamstring tendons are the most commonly used grafts in ACL reconstruction worldwide. There are several ways to prepare the graft using these tendons. One can prioritize increasing the diameter of an isolated intra-articular graft or alternatively, using one graft limb as an extra-articular reinforcement via the anterolateral ligament (ALL) reconstruction, with both options aiming to reduce the re-rupture rate relative to traditional quadrupled hamstring grafts.\n\nObjective: To compare, through a prospective and randomized clinical trial, intra and extra-articular ACL reconstruction with ALL using hamstring autograft versus isolated anatomical ACL reconstruction using quintuple or sextuple hamstring autograft.\n\nMethods: 146 patients will be randomized into two groups of 73 patients. Patients included in the study will be evaluated preoperatively and after surgery at 3, 6, 9, 12, and 24 months postoperatively. The primary outcomes will be clinical failure rate and graft rerupture rate. Secondary outcomes will include functional capacity assessed through IKDC, Lysholm KOOS, and Tegner scores, pain using the VAS, as well as stability assessed by digital rolimeter and objective IKDC. Kinesiophobia and anxiety will be measured using the Tampa scale and Anxiety and Depression scale.\n\nKeywords: Rupture, Anterior Cruciate Ligament, Anterior Cruciate Ligament Reconstruction",[284,285],"Anterior Cruciate Ligament Rupture","Ligament Knee Injury",[287,288,289],"Rupture","Anterior Cruciate Ligament","Anterior Cruciate Ligament Reconstruction","2025-03-29",{"date":292,"type":41},"2025-04-03",{"date":294,"type":41},"2022-08-01",{"date":296,"type":21},"2027-06-01",{"name":47,"class":48},2,{"id":300,"slug":4,"hasResults":10,"nctId":301,"briefTitle":302,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":164,"sex":16,"minAge":305,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":22,"phases":308,"briefSummary":309,"conditions":310,"keywords":312,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":49},"100585707","NCT06905860","Intra-articular Infiltration of Platelet-Rich Fibrin vs Corticosteroid in Mild to Moderate Knee Osteoarthritis","iPRF","Inclusion Criteria:The following inclusion criteria will be followed:\n\n* Age 50 years or older\n* Who have not improved with non-surgical treatment for at least 3 months, ability to sign a consent form, average visual analog scale \\> 40\u002F100 (over at least 7 days in the previous month)\n* Mild or moderate knee osteoarthritis diagnosed by radiographic imaging grade 2 or 3 according to the Kellgren-Lawrence classification.\n\nExclusion Criteria: The exclusion criteria will be:\n\n-Absence from work due to disability benefits or income reduction assistance (worker's compensation). Whenever one of the investigators believes that a participant may be simulating a worse health condition than reality to receive financial assistance with work absence, they will be excluded from the study.\n\nThe following non-inclusion criteria will be observed:\n\n* Angular deviation \\>10º of varus or valgus in relation to the anatomical neutral axis in the coronal plane assessed clinically with a goniometer (anatomical axis of the femur x anatomical axis of the tibia \\> 4º varus or \\> 16º valgus)\n* Body Mass Index (BMI)\\>35 or \\\u003C18\n* Smoking\n* Autoimmune inflammatory disease - rheumatological\n* Diabetes - with HbA1c \\> 7\n* Chronic kidney disease\n* Coagulopathies\n* severe cardiovascular diseases\n* infections or immunodeficiencies\n* active or treated malignant neoplasia\n* use of NSAIDs in the last month\n* use of corticosteroids in the last 3 months\n* platelets \\\u003C 150,000\n* recent intra-articular corticosteroid injection or recent HA injection (in the last 6 months)\n* pregnancy or suspected pregnancy\n* psychiatric disorders.","50 Years",{"count":307,"type":21},90,[168],"Methodology: Randomized double-blind clinical trial comparing intra-articular injection of Platelet-Rich Fibrin (PRF) versus intra-articular injection of corticosteroids in mild to moderate arthrosis of the knee. Inclusion criteria: Age 50 years or older, who have not improved with non-surgical treatment for at least 3 months, ability to sign informed consent, mean visual analogue scale \\> 40\u002F100 (over at least 7 days during the month anterior), mild or moderate knee arthrosis diagnosed by grade 2 or 3 radiographic imaging according to the Kellgren-Lawrence classification. Inclusion criteria: angular deviation \\>10º of varus or valgus in relation to the anatomical neutral axis in the coronal plane clinically evaluated with a goniometer (femur anatomical axis x tibial anatomical axis \\> 4th varus or \\> 16th valgus), BMI \\>35 or \\\u003C18, smoking , autoimmune inflammatory disease - rheumatologic, diabetes - with glycated Hb \\> 7, chronic kidney disease, coagulopathies, severe cardiovascular diseases, infections or immunodeficiencies, malignant neoplasm in activity or under treatment, use of NSAIDs in the last month, use of corticosteroids in the last 3 months, platelets \\\u003C 150,000, recent intra-articular corticosteroid infiltration or recent Hyaluronic acid infiltration (within the last 6 months), pregnancy or suspected pregnancy, psychiatric disorders. Exclusion criteria: when one of the investigators considers that the participant may be simulating a worse health state than the real one in order to receive financial assistance with the absence from work, he will be excluded from the work. Primary outcome: WOMAC. Secondary outcomes: Visual Analogue Pain Scale. Evaluation moments: inclusion and after the procedure at 3, 6, 12, 18 and 24 months. Sample calculation: 90 patients, 45 patients in each group, considering 15% loss to follow-up and aiming to reach a power of 0.8 and an alpha value of 0.5.",[311],"Gonarthrosis; Primary",[313,314],"gonarthrosis","i-PRF","2025-03-24",{"date":317,"type":41},"2025-04-02",{"date":319,"type":21},"2025-06-01",{"date":321,"type":21},"2027-09-01",{"name":47,"class":48},{"id":324,"slug":4,"hasResults":10,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":329,"targetDuration":4,"studyType":22,"phases":331,"briefSummary":332,"conditions":333,"keywords":336,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":49},"100582047","NCT06858228","Comparison of Denervation Techniques for the Treatment of Knee Osteoarthritis: Continuous Ablative Radiofrequency Vs. Chemical Denervation with Absolute Alcohol","Comparison of Denervation Techniques for the Treatment of Knee Osteoarthritis: a Randomized Clinical Trial of Continuous Ablative Radiofrequency Vs. Chemical Denervation with Absolute Alcohol","Inclusion Criteria:\n\n* Adults aged ≥ 18 years.\n* Knee pain for more than 3 months.\n* Clinical and imaging-confirmed diagnosis of knee osteoarthritis, based on X-ray, ultrasound, or magnetic resonance imaging (MRI).\n\nExclusion Criteria:\n\n* History of major joint interventions, such as previous knee surgery or arthroplasty.\n* Severe joint effusion.\n* Coagulation disorders or other clinical contraindications for the procedure.\n* Uncontrolled comorbidities that increase procedural risk.\n* Body mass index (BMI) \\> 35.\n* Cognitive impairment that affects the ability to understand and respond to pain assessment instruments.",{"count":330,"type":21},288,[24],"This randomized clinical trial compares two minimally invasive treatments for knee osteoarthritis pain that has not responded to conventional therapies. The study evaluates the effectiveness and safety of continuous ablative radiofrequency, which uses heat energy to disrupt pain signals, and chemical denervation with absolute alcohol, which involves an injection to reduce pain transmission. Participants will be randomly assigned to one of the treatments, and their pain levels, mobility, and quality of life will be monitored over time to determine which method provides better pain relief.",[334,335],"Osteoarthritis Knee","Chronic Pain",[337,335,338,339,340,341,342,343,344,345],"Knee Osteoarthritis","Denervation","Radiofrequency Ablation","Chemical Neurolysis","Alcohol Neurolysis","Genicular Nerve Ablation","Minimally Invasive Pain Management","Interventional Pain Treatment","Pain Relief","2025-03-06",{"date":348,"type":41},"2025-03-11",{"date":350,"type":21},"2025-04",{"date":352,"type":21},"2026-12",{"name":47,"class":48},{"id":355,"slug":4,"hasResults":10,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":360,"targetDuration":4,"studyType":22,"phases":362,"briefSummary":363,"conditions":364,"keywords":369,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":298},"100335169","NCT03643926","Arthroscopic Versus Open Brostrom for Ankle Instability","Arthroscopic Versus Open Brostrom for Ankle Instability: a Randomized Clinical Trial","Inclusion Criteria:\n\n* Individuals must be older than 18 and younger than 65 years of age, both genders;\n* Participants must be experiencing instability symptoms at the ankle over the last six months;\n* Clinical diagnosis of ankle instability, defined as the presence of at least one previous ankle sprain associated with a current instability sensation by the patient and the presence of a positive anterior drawer test; the previous lateral ligament injury must be confirmed by Magnetic Resonance Imaging (MRI) findings.\n\nExclusion Criteria:\n\n* Previous surgery involving the affected foot or ankle;\n* History or documented evidence of autoimmune or peripheral vascular diseases;\n* History or documented evidence of peripheral neuropathy (nervous compression syndrome, tarsal tunnel syndrome) or systemic inflammatory disease a (rheumatoid arthritis, spondylitis, Reiter Syndrome, etc.);\n* Associated injuries, such as osteochondral lesions, tendon ruptures and fractures.\n* Associated instability, such as syndesmotic and medial instability.\n* Cavovarus foot;\n* BMI over 35;\n* Previous infiltration in the ankle over the six months preceding the initial assessment;\n* Pregnancy;\n* Any condition that represents a contraindication of the proposed therapies;\n* Impossibility or incapacity to sign the informed Consent Form;\n* History or documented evidence of blood coagulation disorders (including treatment with anti-coagulants, but excluding aspirin);\n* Use of heart pacemaker;\n* Presence of infectious process (superficial on skin and cellular tissue, or deep in the bone) in the region to be treated;",{"count":361,"type":21},98,[24],"Background: Ankle sprains are among the most prevalent lesions in primary care. A substantial number of these ligament lesions will develop ankle instability and require a surgical procedure. The Brostrom-Gould technique is the standard surgical approach for this condition, providing excellent results over the years. Thru the last decades, the arthroscopic Brostrom has gain popularity and support by several studies. Yet, there is no consensus regarding the best procedure to treat ankle instability nowadays.\n\nHypothesis: The arthroscopic Brostrom technique will present better levels of pain and function when compared to the standard open approach.\n\nDesign: blinded, in parallel groups, multicentric, randomized, clinical trial.\n\nMaterials and Methods: 98 patients with a diagnosis of chronic ankle instability, referred from primary or secondary health care services, will be assessed and enrolled in this study. Participants will be divided in two groups (randomized by sequentially numbered identical envelopes, which will be administered serially to participants), one containing the open Brostrom repair technique and the other comprehending the arthroscopic Brostrom approach. The assessments will occur in 3, 6, 12, 24 and 48 weeks. Patients will be evaluated primarily by complications and secondarily the Cumberland Ankle Instability Tool (CAIT), American Orthopedic Foot and Ankle Society (AOFAS), the Visual Analogue Scale (VAS), the Foot Function Index (FFI) and the 36 Item Short Form Health Survey (SF-36). The investigators will use Comparison of Two Proportions via relative frequency analysis, the Pearson Correlation the Chi-Square test and the ANOVA for statistical analyses.\n\nDiscussion: This study intends to establish if the arthroscopic Brostrom technique can produce excellent and reliable results when treating chronic ankle instability. A shorter surgical time, a better cosmetic appearance and a smaller soft tissue injury would support the choice for this procedure if the outcomes could be compared to the open approach.",[365,366,367,368],"Ankle Sprains","Instability, Joint","Ligament Injury","Surgery",[370,371,372,373,374],"ankle","instability","brostrom","open","arthroscopic","2024-09-26",{"date":377,"type":41},"2024-09-27",{"date":379,"type":41},"2019-06-01",{"date":381,"type":21},"2027-12-05",{"name":47,"class":48},{"id":384,"slug":4,"hasResults":10,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":4,"eligibilityCriteria":388,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":389,"enrollmentInfo":390,"targetDuration":4,"studyType":22,"phases":392,"briefSummary":393,"conditions":394,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":402,"locationsCount":4},"100557979","NCT06545149","SUPPLEMENTATION WITH BETA GLUCAN AND ADAPTATIVE RESPONSE.","SUPPLEMENTATION WITH FERMENTED AND BALANCED FOOD WITH BETA GLUCAN FAVORS THE INNATE AND ADAPTATIVE RESPONSE OF PATIENTS ADMITTED TO A MEDICAL CLINIC WARD? A RANDOMIZED TRIAL","Inclusion Criteria:\n\nPatients admitted to the medical clinic ward\n\nExclusion Criteria:\n\nPatients unable to swallow","100 Years",{"count":391,"type":21},44,[24],"Abstract: Studies demonstrate that the use of nutritional supplements containing beta-glucans stimulates the immune system, modulates inflammatory activity, and promotes so-called immune training. Beta-glucans are prebiotics that stimulate the growth and activity of gastrointestinal microbiota and inhibit pathogen growth. Nutritional intervention is crucial for patients\\' positive evolution, and providing a supplement with highly bioavailable nutrients can make a difference in their nutritional, metabolic, and immune status. Therefore, the study aims to verify the effectiveness of the innate and adaptive immune response to a nutritionally balanced fermented food, containing oral or enteral beta-glucans, in patients treated at 3 Emergency Care Units in São José do Rio Preto, São Paulo, Brazil. This is a prospective randomized study with a characteristic design involving patients treated in the medical wards of 3 Emergency Care Unit. The following assessments will be conducted: Global Subjective Assessment for adults and Mini Nutritional Assessment for the elderly, Sociodemographic, and Laboratory Evaluation.",[395],"Clinical Course","2024-08-06",{"date":398,"type":41},"2024-08-09",{"date":400,"type":21},"2024-10",{"date":215,"type":21},{"name":47,"class":48},{"id":404,"slug":4,"hasResults":10,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":4,"eligibilityCriteria":408,"healthyVolunteers":164,"sex":16,"minAge":17,"maxAge":409,"enrollmentInfo":410,"targetDuration":4,"studyType":22,"phases":412,"briefSummary":413,"conditions":414,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":428,"locationsCount":49},"100557767","NCT06542393","PBM as Strategy to CABG Anemic Patients Bypass Graft (CABG)","Patient Blood Manegement (PBM) as Perioperative Strategy to Anemic Patients Who Will be Submitted to Coronary Artery Bypass Graft (CABG).","Inclusion Criteria:\n\n* Eletive surgery;\n* Only CABG as procedure;\n* Off pump CABG candidate.\n\nExclusion Criteria:\n\n* Age \\> 80 years;\n* Chronic dialytic kidney disease;\n* Chronic rheumatologic disease;\n* Men with Hb levels \\> 13 g\u002Fdl and \\\u003C 8g\u002Fdl;\n* Women with Hb levels \\> 12 g\u002Fdl and \\\u003C 8g\u002Fdl;\n* Presence of another heart disease requiring surgical intervention;\n* Presence of hepatic insufficiency;\n* Presence of any implantable electronic cardiac device in any cardiac chambers;\n* Pregnancy;\n* Diagnosis of malignant neoplasia;\n* Thrombophilias;\n* Need for Erythropoietin treatment due to any other disease.\n* Recent ischemic event (\\\u003C 3 months).\n* Ejection fraction \\\u003C30%.","80 Years",{"count":411,"type":21},120,[60],"Anemia poses risks during coronary artery bypass grafting (CABG), increasing complications and mortality rates. Blood transfusions in cardiac surgery have negative outcomes, prompting the use of erythropoietin in Patient Blood Management (PBM) to limit transfusion needs and enhance postoperative recovery. EPO can reduce blood component requirements, adverse events, and inflammation in anemic CABG patients. A study aims to minimize transfusions through a PBM anemia treatment protocol for CABG patients, comparing outcomes in three groups: a Control Group (CG), a Non-PBM Group (NPBMG) treated with blood components, and a PBM Group (GPBM) treated with EPO. Parameters include post-op stay, mortality, cardiovascular events, non-cardiovascular events, ICU time, mechanical ventilation duration, vasoactive drug use, inflammatory responses, and cardiac cell death. Analysis will consider demographic and clinical factors, with expectations that GPBM will yield superior results compared to NPBMG and similar or better outcomes than CG.",[415,416,27,417,418,419,420,421],"Anemia","Coronary Disease","Coronary Stenosis","Coronary Occlusion","Systemic Inflammatory Response","Bleeding","Epigenetic Disorder","2024-08-04",{"date":424,"type":41},"2024-08-07",{"date":426,"type":41},"2024-06-01",{"date":75,"type":21},{"name":47,"class":48},""]